Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation?

被引:89
作者
Hilfiker, Andres [1 ]
Kasper, Cornelia [2 ]
Hass, Ralf [3 ]
Haverich, Axel [1 ,4 ]
机构
[1] Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs L, D-30625 Hannover, Germany
[2] Leibniz Univ Hannover, Inst Tech Chem, Hannover, Germany
[3] Hannover Med Sch, Dept Obstet & Gynecol, Lab Biochem & Tumor Biol, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Cardiac Thorac Transplantat & Vasc Surg, D-30625 Hannover, Germany
关键词
Tissue engineering; MSC; Connective tissue; Transplantation; HUMAN UMBILICAL-CORD; MARROW STROMAL CELLS; NEURON-LIKE CELLS; VERSUS-HOST-DISEASE; BONE-MARROW; IN-VITRO; ADIPOSE-TISSUE; HEART-VALVES; VASCULAR GRAFTS; CLINICAL-APPLICATION;
D O I
10.1007/s00423-011-0762-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Transplantation surgery suffers from a shortage of donor organs worldwide. Cell injection and tissue engineering (TE), thus emerge as alternative therapy options. The purpose of this article is to review the progress of TE technology, focusing on mesenchymal stem cells (MSC) as a cell source for artificial functional tissue. MSC from many different sources can be minimally invasively harvested: peripheral blood, fat tissue, bone marrow, amniotic fluid, cord blood. In comparison to embryonic stem cells (ESC), there are no ethical concerns; MSC can be extracted from autologous or allogenic tissue and cause an immune modulatory effect by suppressing the graft-versus-host reaction (GvHD). Furthermore, MSC do not develop into teratomas when transplanted, a consequence observed with ESC and iPS cells. MSC as multipotent cells are capable of differentiating into mesodermal and non-mesodermal lineages. However, further studies must be performed to elucidate the differentiation capacity of MSC from different sources, and to understand the involved pathways and processes. Already, MSC have been successfully applied in clinical trials, e.g., to heal large bone defects, cartilage lesions, spinal cord injuries, cardiovascular diseases, hematological pathologies, osteogenesis imperfecta, and GvHD. A detailed understanding of the behavior and homing of MSC is desirable to enlarge the clinical application spectrum of MSC towards the in vitro generation of functional tissue for implantation, for example, resilient cartilage, contractile myocardial replacement tissue, and bioartificial heart valves.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 111 条
[51]   Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients [J].
Lazarus, HM ;
Koc, ON ;
Devine, SM ;
Curtin, P ;
Maziarz, RT ;
Holland, HK ;
Shpall, EJ ;
McCarthy, P ;
Atkinson, K ;
Cooper, BW ;
Gerson, SL ;
Laughlin, MJ ;
Loberiza, FR ;
Moseley, AB ;
Bacigalupo, A .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (05) :389-398
[52]   Mesenchymal stem cells: progress toward promise [J].
Le Blanc, K ;
Pittenger, MF .
CYTOTHERAPY, 2005, 7 (01) :36-45
[53]   Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells [J].
Le Blanc, K ;
Rasmusson, I ;
Sundberg, B ;
Götherström, C ;
Hassan, M ;
Uzunel, M ;
Ringdén, O .
LANCET, 2004, 363 (9419) :1439-1441
[54]   Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions [J].
Lichtenberg, Artur ;
Tudorache, Igor ;
Cebotari, Serghei ;
Suprunov, Mark ;
Tudorache, Greta ;
Goerler, Heidi ;
Park, Joon-Keun ;
Hilfiker-Kleiner, Denise ;
Ringes-Lichtenberg, Stefanie ;
Karck, Matthias ;
Brandes, Gudrun ;
Hilfiker, Andres ;
Haverich, Axel .
CIRCULATION, 2006, 114 :I559-I565
[55]   Percutaneous Tissue-Engineered Pulmonary Valved Stent Implantation [J].
Lutter, Georg ;
Metzner, Anja ;
Jahnke, Thomas ;
Bombien, Rene ;
Boldt, Jessica ;
Iino, Kenji ;
Cremer, Jochen ;
Stock, Ulrich A. .
ANNALS OF THORACIC SURGERY, 2010, 89 (01) :259-264
[56]   Growth and Differentiation Properties of Mesenchymal Stromal Cell Populations Derived from Whole Human Umbilical Cord [J].
Majore, Ingrida ;
Moretti, Pierre ;
Stahl, Frank ;
Hass, Ralf ;
Kasper, Cornelia .
STEM CELL REVIEWS AND REPORTS, 2011, 7 (01) :17-31
[57]   Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord [J].
Majore, Ingrida ;
Moretti, Pierre ;
Hass, Ralf ;
Kasper, Cornelia .
CELL COMMUNICATION AND SIGNALING, 2009, 7
[58]   Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages [J].
Majumdar, MK ;
Thiede, MA ;
Haynesworth, SE ;
Bruder, SP ;
Gerson, SL .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (06) :841-848
[59]   Fetal stem cells from extra-embryonic tissues: do not discard [J].
Marcus, Akiva J. ;
Woodbury, Dale .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2008, 12 (03) :730-742
[60]   5-azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies [J].
Martin-Rendon, E. ;
Sweeney, D. ;
Lu, F. ;
Girdlestone, J. ;
Navarrete, C. ;
Watt, S. M. .
VOX SANGUINIS, 2008, 95 (02) :137-148